Home / Executive Moves / RSA President Amit Yoran to Join Tenable as Chairman & CEO

RSA President Amit Yoran to Join Tenable as Chairman & CEO

Amit Yoran

Amit Yoran, president of Dell Technologies‘ (NYSE: DVMT) RSA subsidiary, will join Columbia, Md.-based Tenable Network Security as chairman and CEO effective Jan. 3.

Tenable said Thursday Renaud Deraison and Jack Huffard led the security technology company during its search for a new CEO and will continue their respective roles as chief technology officer and president and chief operating officer.

“Amit’s deep security experience and entrepreneurial spirit are a perfect match for the DNA of our company, ” said Deraison.

Dell executive David Goulden stated in an email to employees that the company has selected an individual to succeed Yoran in a move scheduled to take effect in January, according to Reuters, which first reported Yoran’s appointment to lead Tenable.

Yoran told Reuters he will work to grow Tenable and expand the company’s product portfolio through internal development and acquisitions.

Yoran joined RSA through its acquisition of network forensics provider NetWitness, where he served as founder and CEO.

He previously served as founding director of the Department of Homeland Security‘s U.S. Computer Emergency Readiness Team program as well as founder and CEO of managed security service provider Riptech.

Riptech was acquired by Symantec (Nasdaq: SYMC), where Yoran served as vice president of worldwide managed security services.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.